dc.creatorPerez Lloret, Santiago
dc.creatorQuarracino, Cecilia
dc.creatorOtero-losada, Matilde Estela
dc.creatorRascol, Olivier
dc.date.accessioned2022-06-28T13:17:30Z
dc.date.accessioned2022-10-15T15:05:57Z
dc.date.available2022-06-28T13:17:30Z
dc.date.available2022-10-15T15:05:57Z
dc.date.created2022-06-28T13:17:30Z
dc.date.issued2019-02
dc.identifierPerez Lloret, Santiago; Quarracino, Cecilia; Otero-losada, Matilde Estela; Rascol, Olivier; Droxidopa for the treatment of neurogenic orthostatic hypotension in neurodegenerative diseases; Taylor & Francis; Expert Opinion on Pharmacotherapy; 20; 6; 2-2019; 635-645
dc.identifier1465-6566
dc.identifierhttp://hdl.handle.net/11336/160602
dc.identifierCONICET Digital
dc.identifierCONICET
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/4400482
dc.description.abstractIntroduction: L-threo-3,4-dihydroxyphenylserine (droxidopa), a pro-drug metabolized to norepinephrine in nerve endings and other tissues, has been commercially available in Japan since 1989 for treating orthostatic hypotension symptoms in Parkinson’s disease (PD) patients with a Hoehn & Yahr stage III rating, as well as patients with Multiple System Atrophy (MSA), familial amyloid polyneuropathy, and hemodialysis. Recently, the FDA has approved its use in symptomatic neurogenic orthostatic hypotension (NOH). Areas covered: The authors review the effects of droxidopa in NOH with a focus on the neurodegenerative diseases PD, MSA, and pure autonomic failure (PAF). Expert opinion: A few small and short placebo-controlled clinical trials in NOH showed significant reductions in the manometric drop in blood pressure (BP) after posture changes or meals. Larger Phase III studies showed conflicting results, with two out of four trials meeting their primary outcome and thus suggesting a positive yet short-lasting effect of the drug on OH Questionnaire composite score, light-headedness/dizziness score, and standing BP during the first two treatment-weeks. Results appear essentially similar in PD, MSA, and PAF. The FDA granted droxidopa approval in the frame of an ‘accelerated approval program’ provided further studies are conducted to assess its long-term effects on OH symptoms.
dc.languageeng
dc.publisherTaylor & Francis
dc.relationinfo:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.1080/14656566.2019.1574746
dc.relationinfo:eu-repo/semantics/altIdentifier/url/https://www.tandfonline.com/doi/full/10.1080/14656566.2019.1574746
dc.rightshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.rightsinfo:eu-repo/semantics/restrictedAccess
dc.subjectDROXIDOPA
dc.subjectMULTIPLE SYSTEM ATROPHY
dc.subjectNEUROGENIC ORTHOSTATIC HYPOTENSION
dc.subjectPARKINSON’S DISEASE
dc.subjectPURE AUTONOMIC FAILURE
dc.subjectSYNUCLEINOPATHIES
dc.titleDroxidopa for the treatment of neurogenic orthostatic hypotension in neurodegenerative diseases
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:ar-repo/semantics/artículo
dc.typeinfo:eu-repo/semantics/publishedVersion


Este ítem pertenece a la siguiente institución